Recombinant alkaline phosphatase

Drug Profile

Recombinant alkaline phosphatase

Alternative Names: Human recombinant alkaline phosphatase; recAP; Recombinant optimised human alkaline phosphatase

Latest Information Update: 29 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AM-Pharma Holding
  • Developer AM-Pharma
  • Class Phosphoric monoester hydrolases
  • Mechanism of Action Endotoxin inhibitors; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypophosphatasia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase II Acute kidney injury
  • Preclinical Hypophosphatasia; Ulcerative colitis
  • Discontinued Septic shock

Most Recent Events

  • 22 May 2017 AM-Pharma completes enrolment in the STOP-AKI phase II trial for Acute kidney injury in Austria, Belgium, Czech Republic, Finland, France, Italy, Netherlands, Spain, United Kingdom and USA
  • 10 May 2016 Pharmacokinetics data from a phase I trial in Acute kidney injury released by AM-Pharma
  • 26 Apr 2016 Recombinant alkaline phosphatase receives Fast Track designation for Acute kidney injury [IV,Infusion] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top